



**BlueCross
BlueShield**

Federal Employee Program.

OXERVATE (cenegermin-bkbj)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Oxervate (cenegermin-bkbj) is a recombinant human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity and low-affinity nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity (1).

Regulatory Status

FDA-approved indication: Oxervate is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis (1).

Patients should remove contact lenses before applying Oxervate and they may be reinserted 15 minutes after administration (1).

The safety and effectiveness of Oxervate in pediatric patients less than 2 years of age have not been established (1).

Summary

Oxervate (cenegermin-bkbj) is a recombinant human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity and low-affinity nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity. The safety and effectiveness of Oxervate in pediatric patients less than 2 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Oxervate while maintaining optimal therapeutic outcomes.

References

1. Oxervate [package insert]. Boston, MA: Dompe U.S. Inc.; December 2024.